Aspirin in the Prevention of Cardiovascular Disease and Cancer

Area of Science:

• Cardiology
• Gastroenterology
• Oncology

Background:

• Low-dose aspirin is a cornerstone for secondary prevention of cardiovascular disease (CVD).
• The efficacy and safety of aspirin for primary CVD prevention are still under investigation.
• Emerging evidence suggests potential benefits of aspirin in preventing certain cancers, such as colorectal cancer.

Purpose of the Study:

• To evaluate the current evidence on aspirin's role in primary prevention of cardiovascular disease.
• To assess the balance between aspirin's benefits (cardioprotection, cancer prevention) and risks (gastrointestinal bleeding).
• To determine if aspirin is warranted for primary prevention in apparently healthy individuals.

Main Methods:

• Review of older and more recent randomized controlled trials (RCTs) on aspirin for CVD prevention.
• Analysis of preclinical and clinical data regarding aspirin's effects on cancer.
• Assessment of bleeding risks associated with aspirin use, particularly in older populations.

Main Results:

• Older RCTs indicated aspirin reduced myocardial infarction but increased gastrointestinal bleeds without affecting mortality.
• Recent trials show diminished aspirin benefits for CVD, potentially due to concurrent cardioprotective measures.
• Gastrointestinal bleeding risk persists, with higher incidence in elderly patients.

Conclusions:

• Aspirin's role in primary CVD prevention is not definitively established.
• The potential anticancer effects of aspirin require further investigation.
• Current evidence does not fully support the routine use of aspirin for primary prevention of CVD and cancer in healthy individuals.